ArticleEuropean journal of medical research2025
Cerebrospinal fluid visinin-like protein, glial cell line-derived neurotrophic factor, and cadherin-6 alterations in pregnancy complications.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum visinin-like protein-1 levels in preeclampsia: a cross-sectional pilot study.BMC pregnancy and childbirth · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis exploratory study examined cerebrospinal fluid (CSF) biomarker profiles in pregnancy complications, investigating visinin-like protein 1 (VILIP-1), glial cell line-derived neurotrophic factor (GDNF), and cadherin-6 as indicators of potential central nervous system involvement.
methodsA prospective cross-sectional analysis enrolled 110 pregnant women undergoing cesarean delivery with spinal anesthesia: healthy pregnancies (n = 55) and complicated pregnancies (n = 55) comprising hypertensive disorders (n = 21), gestational diabetes (n = 14), preterm labor (n = 12), and fetal growth restriction (n = 8). CSF biomarker concentrations were quantified via enzyme-linked immunosorbent assay.
resultsComplicated pregnancies demonstrated elevated VILIP-1 (median 8.46 [IQR 6.94-10.32] vs. 6.12 [IQR 4.87-7.35] ng/mL, p < 0.001) and reduced GDNF (185.4 [IQR 156.2-208.7] vs. 242.7 [IQR 214.3-274.8] pg/mL, p < 0.001) compared to controls. Cadherin-6 exhibited modest reduction (78.2 [IQR 65.4-92.8] vs. 94.5 [IQR 82.6-108.3] ng/mL, p = 0.003). Stratified analysis identified hypertensive disorders as the primary driver of biomarker alterations (VILIP-1: + 58%; GDNF: - 33%). Restricted correlation analysis within the hypertensive subgroup demonstrated robust associations between biomarkers and clinical severity markers. Multivariate logistic regression confirmed VILIP-1 (aOR 2.14, 95% CI 1.43-3.20, p < 0.001) and GDNF (aOR 0.48, 95% CI 0.32-0.72, p < 0.001) as independent predictors.
conclusionCSF biomarker alterations in complicated pregnancies, predominantly driven by hypertensive disorders, suggest neuroinflammatory activation and compromised neuroprotection. The heterogeneous grouping of pathophysiologically distinct complications constitutes a primary methodological limitation. These preliminary findings necessitate validation through adequately powered, disease-specific investigations before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.